The US FDA has approved four COVID vaccines targeting the XFG variant for the 2026-2027 season, developed by Moderna, Pfizer and BioNTech, Novavax, and Sanofi. While the vaccines are available for high-risk individuals, the CDC’s lack of guidance leads to… Read More »FDA approves four new COVID vaccines for the 2026-27 season
On August 19, 2026, Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran, significantly reduces melanoma recurrence and spread in a phase 3 trial. Combining intismeran with Merck’s Keytruda showed notable improvements in patient outcomes, marking a pivotal… Read More »New mRNA vaccine cuts recurrence and spread of melanoma
Moderna’s mRNA-1010 flu vaccine has received FDA approval for adults aged 50 and older, marking it as the first mRNA-based flu vaccine in the U.S. It demonstrates 26.6% higher effectiveness than standard vaccines. While adverse events were more frequent, most… Read More »FDA approves first mRNA flu vaccine for people over 50
Merck settled recent Gardasil lawsuits for approximately $50 million, despite winning prior litigation, primarily to avoid high litigation costs. The settlement does not validate the plaintiffs’ claims, as studies show no link between Gardasil and their alleged conditions. The Vaccine… Read More »Explanation of the settlement of Gardasil lawsuits by Merck
A recent study reveals that an individualized mRNA vaccine for surgically resected melanoma, developed by Moderna and Merck, significantly reduces recurrence and distant spread risks over a five-year period. When combined with Keytruda, it boosts survival rates, showcasing the potential… Read More »Melanoma mRNA vaccine halves risk of recurrence, metastasis
Recent developments indicate promising long-term results from clinical trials for an mRNA vaccine targeting pancreatic cancer, a notoriously hard-to-diagnose and treat disease. This individualized vaccine stimulates an immune response against cancer cells and may enhance patient outcomes when used in… Read More »Pancreatic cancer mRNA vaccine showing long-term success
A recent clinical trial revealed that Moderna’s mRNA flu vaccine showed a 26.6% higher effectiveness than standard flu vaccines among adults over 50. While it had more reported adverse effects, most were mild. Concerns persist about regulatory approval and acceptance,… Read More »Moderna mRNA flu vaccine more effective than standard shot
Pfizer and Valneva reported positive results from their LB6V Lyme disease vaccine trial, showing efficacy rates of 73.2% to 74.8% after immunization. Lyme disease is prevalent in North America and Europe, with about 476,000 and 130,000 cases annually, respectively. The… Read More »Lyme disease vaccine shows excellent clinical trial results
On March 23, 2026, Pfizer and Valneva announced their Lyme disease vaccine candidate demonstrated 70% efficacy in phase 3 clinical trials. The vaccine could gain regulatory approval, becoming the only Lyme disease vaccine available. Lyme disease, caused by Borrelia bacteria… Read More »Lyme disease vaccine 70% efficacy in phase 3 clinical trials
On February 10, 2026, the FDA denied Moderna’s biologics license application for its mRNA flu vaccine, citing insufficient trial data. After a meeting with Moderna on February 18, the FDA agreed to review a revised application, aiming for potential approval… Read More »FDA reverses itself and will review Moderna mRNA flu vaccine